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ABSTRACT 
   CD27 is a biomarker associated with both T-cells and B-cells activation .Plasma soluble CD27 
(sCD27) was identified as  a marker of disease outcome in Human Immunodeficiency Virus (HIV) 
infection .Testing of plasma sCD27 represents a good tool to monitor the change of immune activation 
during HIV infection.We sought to analyses role of Hepatitis C Virus (HCV) and also GB Virus type C 
(GBV-C) co-infections on HIV-related immune activation, through measuring sCD27 plasma levels. 
Blood samples from a total of 86 patients with HIV infection were taken. Plasmas were analyzed for 
HCV using serologic test and GBV-C by reverse transcriptase polymerase chain reaction (RT-PCR). 
CD4+ and CD8+T-cell counts were evaluated by CD3/CD4+ and CD3/CD8+ double staining of whole 
blood followed by flow cytometric analysis .Then  Cross-sectional comparison of sCD27 plasma levels 
was carried out among patients : HIV (n=20), HIV/ GBV-C (n=14), HIV/ (HCV) (n=26) and 
HIV/HCV/GBV-C (n=26).Plasma level of sCD27 was higher in HIV/HCV/GBV-C patients as compared 
to HIV mono-infected patients (p= 0.006) and based on results there was significant differences in the 
plasma levels of sCD27 between HIV-infected individuals with and without HCV coinfection (P=0.017) 
and also correlation between sCD27 and percent of CD4+T-cells was in highest level among HIV/HCV 
co-infected patients group [r= -0.59 (p=0.001)]. High levels of sCD27 among HIV/HCV patients argues 
in favor of sCD27 plasma level determination for monitoring of clinical features among HIV/HCV 
coinfected patients. 
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INTRODUCTION 
   Considering that immune activation 
contributes to the HIV pathogenesis, parameters 
reflecting the activation of immune response are 
attractive candidates as HIV surrogate markers 
.Surrogate markers can reflects other parts of 
HIV pathogenesis that no detectable based on 
just  CD4+ T cell counts and viral load 
measurements [1].  
CD27 was associated with HIV progression in 
other setting and was identified as a HIV 
surrogate marker [2]. In chronic clinical 
conditions such as persistent virus infection and 
autoimmune disease that are associated with an 
enhanced activation of the immune system, an 
increase in plasma soluble CD27 (sCD27) level 
has been documented [3]. CD27 regulates 
cellular activity in subsets of immune cells. In 
normal immune responses, CD27 signaling  
 
appears to be limited. However, continuous 
CD27–CD70 interactions may cause immune 
deregulation in condition of chronic immune 
activation [4].  
GBV-C is a flavivirus closely related to HCV, 
with approximately 30% amino acid sequence 
homology that initially reported to be associated 
with post-transfusion hepatitis in humans. 
However, several research groups demonstrated 
that persistent GBV-C infections are 
asymptomatic and there is no relation between 
virus infection and human disease. Nowadays 
GBV-C introduces as a harmless virus or 
orphan virus. Many clinical and 
epidemiological studies have suggested a 
beneficial effect of GBV-C co-infection on the 
course of HIV-1 infection, however not all 
studies confirmed the results [5, 6]. Definitive 
mechanisms of effect of GBV-C -renamed as 





human pegivirus [5] - on immune system of 
HIV patients need to be identified yet. 
HCV coinfection is associated with a higher 
mortality among HIV patients and so more 
research is needed to clarify mechanism of 
HIV/HCV interaction to improve treatment 
options for co-infected individuals [7, 8]. 
Main objective of this study was to demonstrate 
the impact of co-infection with pathogenic 
(HCV) vs. non-photogenic (GBV-C) viruses on 
immune system among HIV-infected 
individuals and in this context to evaluate 
plasma sCD27 as marker for immune activation. 
We demonstrated increased plasma levels of 
soluble CD27 among HIV infected patients with 
HCV co-infection. 
 
MATERIAL AND METHODS 
 Under study Subjects 
 Study subject were patients being seen at the 
Iranian Blood Transfusion (IBTO) during April 
and September 2011 in Tehran. Sample were 
serologically determined as HIV positive via 
ELISA assay and subsequently confirmed by 
Western blotting in the Central Research 
Laboratory of IBTO. The patients were at 
various stages of HIV infection, ranging from 
asymptomatic to those fitting the CDC case 
definition of AIDS. Study participants signed 
informed consent approved by the institutional 
review board for human studies at IBTO. 
 Blood samples from a total of 86 patients with 
HIV infection were taken and were enrolled in 
the sCD27 plasma levels determination. They 
were stratified in to four groups according to the 
GBV-C and HCV coinfection status:  HIV 
(n=20), HIV/ GBV-C (n=14), HIV/ HCV 
(n=26) and HIV/HCV/GBV-C (n=26). 
 Laboratory Procedures 
 Analysis of lymphocyte Subpopulations 
 Whole blood analyzed for the percentage of 
CD4+ and CD8+ T-cells by CD3/CD4+ and 
CD3/CD8+ double staining method and flow 
cytometric analysis on lymphocyte population 
gate. 
 Detection of GBV-C  
 Plasma GBV-C RNA was detected by RT-PCR 
as previously described (9) with some 
modifications. Total RNA was extracted from 
200 µL of plasma using the high pure viral 
nucleic acid kit (Roche, Germany), according to 
the manufacturer’s instructions .Five µL of 
extracted RNA was added to RT mix containing 
dNTP, random hexamer primer, RNase inhibitor 
and murine leukemia virus reverse transcriptase. 
cDNA synthesis was performed at 40ċ for 40 
min. cDNA was then added to PCR mix 
containing Taq polymerase, dNTP and primer 
pairs(forward, flanking NS5a 77-101  region : 
5-CTC TTT GTG GTAGTA GCC GAG AGA 
T-3, and reverse,flanking  NS5a 211- 188 
region: 5- CGA ATG AGT CAG AGG ACG 
GGG TAT-3),designed based on the previously 
reported viral genome . Amplification was 
performed at 95ċ for 5 min, and then 45 cycles 
of 94ċ for 45 sec, 55ċ for 45 sec and , 72ċ for 45 
sec with a 5-min final extension at 72 ċ. 
Amplicons were detected by gel electrophoresis 
on an ethidium bromide-stained 2% agarose gel 
under UV light. Negative (HGV RNA negative 
plasma) and positive (HGV RNA positive 
plasma) controls were included in each run. 
Finally, the product band was selected and 
purified with the illustra microspin columns Kit 
(GE health care, USA), and positive cases were 
reconfirmed by PCR products sequencing. 
 SCD27 plasma level 
 To measure the plasma levels of sCD27, a 
sandwich enzyme-linked immunosorbent assay 
(human sCD27 ELISA, eBioscience, UAS) was 
used. Briefly, subjects’ plasma was added to 
mouse anti- human CD27 coating antibodies 
that were concomitant with a biotin-conjugated 
anti-human sCD27 antibody and Streptavidin-
HRP. After 3 h incubation and washing, to 
remove unbound materials, substrate solution 
was added to the wells. A colored product was 
formed in proportion to the amount of human 
sCD27 present in the sample. The reaction was 
terminated by addition of acid and absorbance 
was measured at 450 nm. A standard curve was 
prepared from seven sCD27 standard dilutions 
and human sCD27 sample concentration 
determined. This assay detected sCD27 
quantities as low as 0.2 U/ml.  
 Anti-HCV assay  
 Plasma samples were screened for HCV 
infection using a commercial ELISA kits (Acon 
Laboratories, USA) to detect anti-HCV 
antibodies based on the manufacturer’s 
protocol.  
 Statistical Analysis  
 All statistical analyses were carried out using 
the statistical program SPSS (version 17; SPSS, 
Chicago, IL); p Values of 0.05 or less were 
considered significant and p values were two-
sided throughout. Kolmogorov- Smirnov tests 
were performed to determine whether variable 





distributions were Gaussian. Because of non- 
normal distributions, nonparametric statistics 
were used. The Mann-Whitney U –test was 
used for dual group comparison .Correlations 
between sCD27 concentration and other 
parameters were performed by the Pearson or 
Spearman's rank test. 
 
RESULTS 
   Plasma sCD27 in relation to CD4 positive T 
cell percentage, sex and age 
Patients with CD4/CD8<1 had higher sCD27 
plasma levels than patients with CD4/CD8 ≥1 
(Fig.1).According to our finding the plasma 
level of sCD27 was moderately higher in males 
as compared to females; however, this 
difference was not statically significant. The 
lowest levels of sCD27 in females (51.67 U/ml) 
belonged to an HIV/GBV-C co-infected 31years 
old patient with CD4/CD8= 40.5/38.3 and the 
highest levels (466.12 U/ml) was seen in a 32 
years old female with CD4/CD8 = 9.5/66.3 that 
belonged to   HIV/HCV/GBV-C coinfected 
patients. The lowest levels of sCD27 in males 
was 48.27 U/ml was seen in a 25 years old man 
with CD4/CD8 = 43.1/31.9 that belonged to   
HIV/HCV coinfected patients and the highest 
levels was 320.85 U/ml which belonged to an 
HIV/HCV co-infected 53years old patient with 
CD4/CD8= 6/58.5.  
Our study did not show a significant correlation 
of alterations between the level of plasma 
sCD27 and age of patients (r= 0.109, p = 0.35), 
confirming data reported previously (10). 
Negative correlation was seen between the 
percentages of CD4 positive T cells and plasma 






of the linear model was 0.24 
(p<0.001) that means twenty four percent of 
changes in CD4 count might be predictable with 
knowing sCD27 concentration among HIV 





Figure 1. Evaluating of sCD27 plasma levels in relation to CD4 positive T cell percentage. Patients with CD4/CD8<1(n=54) 

















Figure 2.  There is a correlation between sCD27 plasma levels in relation to CD4 positive T cell percentage (Correlation 






Figure.3. Dependency of sCD27 concentration and co-infection. Box plots represent the 10th, 25th, 50th, 75th, and 90th 
percentiles for the sCD27 concentration. 












Dependency of sCD27 concentration and 
Coinfection 
Based on the simultaneous infection of HIV 
positive patients with GBV-C and HCV, eighty 
six under study cases were stratified into four 
groups: HIV monoinfected (n=20), HIV/GBV-C 
(n=14), HIV/HCV (n=26) and HIV/HCV/GBV-
C (n=26) co-infected patients. Box plots 
represent the 10th, 25th, 50th, 75th, and 90th 
percentiles for the sCD27 concentration and are 
shown in figure 3. The lowest levels of sCD27 
(48.27 U/ml) was seen in a 25 years old man 
with CD4/CD8 = 43.1/31.9 that belonged to   
HIV/HCV co-infected patients and the highest 
levels (466.12 U/ml) was seen in a 32 years old 
female with CD4/CD8 = 9.5/66.3 that belonged 
to   HIV/HCV/GBV-C co-infected patients.  
Plasma level of sCD27 was higher in 
HIV/HCV/GBV-C patients as compared to HIV 
mono-infected patients this difference was 
statically significant (p=0.006). 
There was significant difference in the sCD27 
concentration between HIV-infected individuals 
with and without HCV coinfection (P=0.017) 
but, there was no significant difference in the 
sCD27 concentration between HIV-infected 
individuals with and without GBV-C 
coinfection (Figure 4). We also investigate the 
correlation of sCD27 in relation to CD4 positive 
T cell count for groups separately and found 
that sCD27 determination coefficient R
2
 of the 
linear model were approximately similar in HIV 
monoinfected, HIV/GBV-C and 
HIV/HCV/GBV-C co-infected patients (0.136, 
0.175 and 0.143 respectively) but among 
HIV/HCV co-infected patients group was in 


















Figure.4 Levels of sCD27 concentration according to HIV 
infection and HCV and/or GBV-C co-infection. Significant 
difference in the sCD27 concentration between HIV-
infected individuals with and without HCV coinfection 




























Figure.5. Dependency of sCD27 concentration and Coinfection status. (A)HIV monoinfected, (B) HIV/GBV-C, (C) HIV/HCV 










   Remarkable efforts have been put into 
association of plasma biomarkers with HIV-1 
disease progression to finding markers, which is 
relatively easy to perform, as a good alternative 
of CD4 count and/or viral load for monitoring 
HIV disease progression. Soluble CD27 is 
proposed to be the most suitable marker for 
monitoring HIV-1 disease progression by 
Messele et al [2]. 
 In this report in agreement with other studies 
our results indicated negative correlation 
between the CD4 positive T cell count and 
plasma sCD27 concentration among HIV 
infected patients [4, 10-15]. 
We sought to analyses role of HCV and GBV-C 
co-infections on HIV-related immune 
activation, through measuring sCD27 plasma 
levels in HIV/GBV-C, HIV/HCV and 
HIV/HCV/GBV-C co-infected patients in 
comparison with monoinfected patients. We 
demonstrated increased plasma levels of soluble 
CD27 among HIV infected patients with HCV 
co-infection. Based on results there was 
significant differences in the plasma levels of 
sCD27 between HIV-infected individuals with 
and without HCV coinfection (P=0.017). 
Correlation between sCD27 and number of 
CD4+T-cells was in highest level among 
HIV/HCV co-infected patients group (Fig5C). 
CD27 can be shed from the cell surface upon 
cell activation. Therefore, higher sCD27 plasma 
levels and also lower CD27 cell surface 
expression in HCV infection are   attributable to 
increased shedding by response to immune 
stimulation (16). Our findings confirm impaired 
induction of CD27 in chronic HCV infection 
reported by Yonkers et al [16].Regulation of 
CD27 is thought to be crucial for immune 
response formation in which impaired CD27 
signaling is known to contribute to lack of a 
sustained memory T cell pool [16]. Therefore 
deregulation of   CD27 levels among HIV/ 
HCV co-infected patients might be contribute to 
inadequate formation of virus specific T cell 
responses during chronic infection and reduced 
responsiveness to immunomodulator therapy 
among HIV/HCV co-infected subjects.  
Given the high prevalence of HCV coinfection 
in HIV patients, there has been a high demand 
in finding new biomarkers of HIV/HCV 
pathogenesis and also finding new markers for 
improving treatment options for coinfected 
individuals under these chronic infection  
 
statuses. The magnitude of sCD27 plasma level 
alterations in relation to clinical conditions like 
post-HCV infection glomerulonephritis and 
other non-AIDS-related causes of death among 
HCV co-infected HIV subjects need to be 
defined. For instance sCD27 is a more sensitive 
marker for renal tubule apoptosis than plasma 
creatinine [17]. Therefore, in certain clinical 
scenarios including post-HCV infection 
glomerulonephritis increased level of sCD27 
seems to be indicative, however, further studies 
should be conducted on HIV/HCV coinfected 
patients with renal dysfunction in order to verify 
this hypothesis.  
As the transmission routes are shared by HIV, 
HCV and GBV-C infections, coinfection is 
common but there is remarkably little published 
about the potential complex interactions among 
GBV-C, HCV, and HIV in triply infected 
subjects and results are lacking for HIV infected 
patients who were infected by both HCV and 
GBV-C [6, 18]. Our data indicate that in higher 
plasma level of sCD27 among our 
HIV/HCV/GBV-C patients (Fig.3), which 
leaves unanswered the question, is GBV-C a 
beneficial infection? Longitudinal studies are 
needed to define the role of GBV-C-associated 
modulation of HIV disease. However existing 
data indicate that in contrast to HCV, GBV-C 
does not induce a more sCD27 plasma level in 
HIV positive patients (Fig.4B). This finding 
supports the theory that GBV-C is not 
pathogenic [18, 19]. 
We confirm that there is some limitation in 
cross sectional study by studying in a single 
time point; however our work generates some 
preliminary finding in role of co-infections on 




   Increased plasma levels of soluble CD27 
among HIV infected patients with HCV but not 
with Human Pegivirus coinfection.sCD27 
seems to be a valuable marker for monitoring of 
clinical features in HIV/HCV coinfection, 
where the immune activation plays a role in 
pathogenesis. More studies are needed to define 
the magnitude of sCD27 plasma level 
alterations in relation to the clinical conditions 
like post infectious glomerulonephritis and 
lymphoma among HIV/HCV patients.  
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